ACCC says agreement to settle Revlimid patent suit could violate cartel laws
The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.
For information on rights and reprints, contact subscriptions@lawyerly.com.au